L. Higgins

P. Ammann, L. Higgins, J. Caverzasio, 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Transgenic mouse brain histopathology resembles early Alzheimer's disease

D. Holtzman, W. Mobley, L. Higgins, 1994, Annals of neurology.

p3 -Amyloid Peptide Has a Unique and Potentially Pathogenic Immunohistochemical Profile in Alzheimer's Disease Brain

G. Murphy, L. Higgins, R. Catalano, 2007 .

Analgesic effects of p38 kinase inhibitor treatment on bone fracture healing

S. Medicherla, M. Meyenhofer, L. Higgins, 2009, Pain.

Early Alzheimer disease-like histopathology increases in frequency with age in mice transgenic for beta-APP751.

L. Higgins, R. Catalano, D. Quon, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?

C. Mantzoros, R. Henry, F. Dunn, 2014, Diabetes Care.

Role of the TGF- b /Alk5 Signaling Pathway in Monocrotaline-induced Pulmonary Hypertension

P. Sehgal, A. Zaiman, R. Tuder, 2008 .

Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression.

S. Rennard, Ying Wang, F. Wen, 2006, Molecular Pharmacology.

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.

P. Richardson, D. Chauhan, T. Hideshima, 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

Inhibitory effect of p38 mitogen‐activated protein kinase inhibitors on cytokine release from human macrophages

A. Nicholson, P. Barnes, L. Donnelly, 2006, British journal of pharmacology.

Selective p38α mitogen-activated protein kinase inhibitor attenuates lung inflammation and fibrosis in IL-13 transgenic mouse model of asthma

S. Medicherla, A. Protter, L. Higgins, 2008, Journal of asthma and allergy.

Selective p 38 α mitogen-activated protein kinase inhibitor attenuates lung in fl ammation and fi brosis in IL-13 transgenic mouse model of asthma

S. Medicherla, A. Protter, L. Higgins, 2008 .

Topical alpha-selective p38 MAP kinase inhibition reduces acute skin inflammation in guinea pig

M. Reddy, S. Medicherla, A. Protter, 2010, Journal of inflammation research.

p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma.

Lingyun Li, S. Medicherla, A. Protter, 2008, Anticancer research.

SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo

M. Weller, W. Wick, M. Platten, 2004, Cancer Research.

p38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells.

Hui Wang, A. Protter, A. Kapoun, 2004, Journal of molecular and cellular cardiology.

A Transgenic Mouse Model of Alzheimer’s Disease

L. Higgins, B. Cordell, 1994 .

Transgenic Mice as a Model of Alzheimer’s Disease

L. Higgins, B. Cordell, 1994 .

Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders.

L. Forno, L. Eng, G. Murphy, 1994, The American journal of pathology.

p38α-Selective Mitogen-Activated Protein Kinase Inhibitor SD-282 Reduces Inflammation in a Subchronic Model of Tobacco Smoke-Induced Airway Inflammation

S. Medicherla, A. Protter, A. Kapoun, 2008, Journal of Pharmacology and Experimental Therapeutics.

Immunological identification of a nicotinic acetylcholine receptor on bovine chromaffin cells

D. K. Berg, L. Higgins, 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

TGF-β Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.

P. Richardson, D. Chauhan, T. Hideshima, 2004 .

Striving for useful phenotypes in β-APP transgenic mice

L. Higgins, B. Cordell, 1995, Neurobiology of Aging.

Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.

L. Higgins, A. DePaoli, 2010, The American journal of clinical nutrition.

A desensitized form of neuronal acetylcholine receptor detected by 3H- nicotine binding on bovine adrenal chromaffin cells [published erratum appears in J Neurosci 1988 Dec;8(12):preceding 4415]

D. Berg, D. K. Berg, L. Higgins, 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Transforming Growth Factor-β Receptor Type 1 (TGFβRI) Kinase Activity but Not p38 Activation Is Required for TGFβRI-Induced Myofibroblast Differentiation and Profibrotic Gene Expression

S. Rennard, Ying Wang, F. Wen, 2006, Molecular Pharmacology.

Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.

M. Weller, W. Wick, A. Protter, 2007, Neuro-oncology.

Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.

R. Orlowski, G. Small, L. Higgins, 2007, Cancer research.

Pharmacological Properties of SD-282 – An α-Isoform Selective Inhibitor for p38 MAP Kinase

S. Medicherla, A. Protter, A. Kapoun, 2008, Pharmacology.

Transforming Growth Factor β Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment

P. Richardson, D. Chauhan, T. Hideshima, 2004, Clinical Cancer Research.

Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases

J. Chirgwin, R. Vessella, L. Suva, 2006, Clinical Cancer Research.

Role of p38 mitogen activated protein kinase in a model of osteosarcoma-induced pain

C. Svensson, T. Yaksh, Yebin Jiang, 2008, Pharmacology Biochemistry and Behavior.

Disease mechanisms and emerging therapies: protein kinases and their inhibitors in myocardial disease

H. Schulman, L. Higgins, M. Anderson, 2006, Nature Clinical Practice Cardiovascular Medicine.

Targeting Endogenous Transforming Growth Factor β Receptor Signaling in SMAD4-Deficient Human Pancreatic Carcinoma Cells Inhibits Their Invasive Phenotype 1

M. Reiss, R. Schwarz, L. Higgins, 2004, Cancer Research.

Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor.

M. Kolb, J. Gauldie, A. Protter, 2005, American journal of respiratory and critical care medicine.

Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

M. Bitzer, A. Verma, S. Kambhampati, 2008, Blood.

Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS. Commentary

M. Bitzer, A. Verma, S. Kambhampati, 2008 .

Ca2+/calmodulin-dependent kinase II triggers cell membrane injury by inducing complement factor B gene expression in the mouse heart.

R. Weiss, J. Thurman, T. Blackwell, 2009, The Journal of clinical investigation.

Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses.

L. Platanias, M. Tallman, A. Nebreda, 2006, Cancer research.

Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling.

M. Reiss, A. Joly, K. Reiss, 2004, Biochemical pharmacology.

P38&agr;-Selective Mitogen-Activated Protein Kinase Inhibitor for Improvement of Cultured Human Islet Recovery

I. Todorov, J. Rawson, Jonathan Shintaku, 2010, Pancreas.

Specific spatial learning deficits become severe with age in β-amyloid precursor protein transgenic mice that harbor diffuse β-amyloid deposits but do not form plaques

J. Bureš, J. Koistinaho, J. Cimadevilla, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Transgenic Mice and Modeling Alzheimer's Disease

L. Higgins, B. Cordell, 1995, Reviews in the neurosciences.

P. Moran, L. Higgins, P. Moser, 1995, Proceedings of the National Academy of Sciences of the United States of America.

β-Amyloid precursor protein transgenic mice that harbor diffuse Aβ deposits but do not form plaques show increased ischemic vulnerability: Role of inflammation

R. Kauppinen, J. Bureš, A. Salminen, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Expression of Human Apolipoprotein E Downregulates Amyloid Precursor Protein-Induced Ischemic Susceptibility

D. Holtzman, R. Kauppinen, J. Koistinaho, 2002, Stroke.

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

G. Roodman, N. Kurihara, G. Schreiner, 2006, Experimental cell research.

Inhibition of Transforming Growth Factor β Signaling Reduces Pancreatic Adenocarcinoma Growth and Invasiveness

Alison Murphy, Lingyun Li, S. Medicherla, 2007, Molecular Pharmacology.

Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.

Lingyun Li, G. Schreiner, S. Medicherla, 2007, Anticancer research.

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

S. Medicherla, A. Protter, B. Cullen, 2009 .

Increased amyloid production from aberrant beta-amyloid precursor proteins.

J. Higaki, L. Higgins, D. Quon, 1994, The Journal of biological chemistry.

p38 MAPK inhibition reduces diabetes-induced impairment of wound healing

S. Medicherla, A. Protter, B. Cullen, 2009, Diabetes, metabolic syndrome and obesity : targets and therapy.

Genetically engineered animal models of human neurodegenerative diseases.

L. Higgins, B. Cordell, 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain.

L. Forno, G. Murphy, L. Higgins, 1996, The American journal of pathology.

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

Constantine Mitsiades, P. Richardson, D. Chauhan, 2004, Oncogene.

Transforming Growth Factor-β Receptor Type 1 (TGFβRI) Kinase Activity but Not p38 Activation Is Required for TGFβRI-Induced Myofibroblast Differentiation and Profibrotic Gene Expression

S. Rennard, Ying Wang, F. Wen, 2006, Molecular Pharmacology.

induced myofibroblast differentiation and pro-fibrotic gene expression

S. Rennard, Ying Wang, F. Wen, 2006 .

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

S. Medicherla, A. Protter, B. Cullen, 2009 .

The Development of INT131 as a Selective PPARγ Modulator: Approach to a Safer Insulin Sensitizer

C. Mantzoros, Linda S. Higgins, L. Higgins, 2008, PPAR research.

P48. Transforming growth factor β receptor I kinase inhibitor and bisphosphonates are additive to reduce breast cancer bone metastases

K. Mohammad, T. Guise, L. Higgins, 2008 .

P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.

Kenneth C. Anderson, Paul G. Richardson, Nikhil C. Munshi, 2004 .

β-App-751 Transgenic Mice: Deficits in Learning and Memory

P. Moran, L. Higgins, P. Moser, 1997 .

A Transgenic Mouse Model of Alzheimer’s Disease

L. Higgins, B. Cordell, 1994 .

Pyrimidine-based inhibitors of CaMKIIdelta.

S. Sideris, Linda S Higgins, J. Higaki, 2008, Bioorganic & medicinal chemistry letters.

DMSOTT-5859-p38 MAPK inhibition reduces diabetes-induced impair

S. Medicherla, A. Protter, B. Cullen, 2009 .

Topical alpha-selective p 38 MaP kinase inhibition reduces acute skin inflammation in guinea pig satyanarayana

M. Reddy, A. Protter, L. Higgins, 2010 .

Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.

A. Verma, S. Parmar, L. Platanias, 2006, Blood.